Background This investigation explores the concept of stigma related to people who use anabolic-androgenic steroids (PWU-AAS) when accessing healthcare services. Anabolic …
AM Barreveld, A Mendelson, B Deiling… - Anesthesia & …, 2023 - journals.lww.com
BACKGROUND TO OPIOID USE DISORDER, TREATMENT PRINCIPLES, AND THE ANESTHESIOLOGIST OUD is defined by the overpowering desire to obtain and use opioids …
R Laing, CA Donnelly - Plos one, 2024 - journals.plos.org
We conduct this research with a two-fold aim: providing a quantitative analysis of the opioid epidemic in the United States (US), and exploring the impact of the COVID-19 pandemic on …
Importance Given the high number of opioid overdose deaths in the US and the complex epidemiology of opioid use disorder (OUD), systems models can serve as a tool to identify …
Background Community stigma toward people with opioid use disorder (OUD) can impede access to harm reduction services and treatment with medications for opioid use disorder …
UG Khatri, MJN Tiako, A Gebreyesus, A Reid… - … -Qualitative Research in …, 2023 - Elsevier
Racial inequities in the treatment of opioid use disorder (OUD) are an urgent and insidious issue, especially in the context of the national opioid overdose crisis. Medications for opioid …
Background Patient-provider shared decision-making is associated with better treatment adherence and pain outcomes in opioid-specific pain management. One possible …
Introduction Xylazine, an α2-adrenoceptor agonist sedative commonly used in veterinary medicine, is not approved for human use. Nevertheless, xylazine-involved overdose rates …
T Caruana - Stigma and Health, 2024 - psycnet.apa.org
Opioid agonist treatment (OAT) is subject to stigma due to its association with criminalized and socially discredited illicit drug use behaviors. This study aimed to explore if the negative …